Finance

Lists
Why is AVH down 6.32%?
Dive Deeper
AVH:ASX
AVITA Medical Inc
A$4.74
-6.32%
(-0.32) 1D
Nov 13, 4:10:12 PM GMT+11  ·   AUD
All symbols
SymbolPriceChange% Change
Generating top insights for AVH...
Open
A$4.90
High
A$4.92
Low
A$4.73
Mkt. cap
743.78M
Avg. vol.
427.45K
Volume
197.74K
52-wk high
A$5.17
52-wk low
A$1.00
Shares outstanding
31.42M
No. of employees
226
Open
A$4.90
High
A$4.92
Low
A$4.73
Mkt. cap
743.78M
Avg. vol.
427.45K
Volume
197.74K
52-wk high
A$5.17
52-wk low
A$1.00
Shares outstanding
31.42M
No. of employees
226
News stories
From web sources and news partners
Profile
Avita Medical is a clinical and commercial company developing and marketing a range of regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are PermeaDerm, a transparent, biosynthetic bilayer wound matrix used for temporary wound coverage after surgical excision of burns or trauma, and Cohealyx, a bovine-derived collagen dermal matrix used by burn and trauma surgeons to treat severe wounds and full-thickness burns by accelerating blood vessel formation in order to prepare damaged wound beds for skin autografts. Wikipedia
About AVITA Medical Inc
CEOJames Corbett
Employees226
Founded1999
HeadquartersValencia, California, United States
SectorHealth Care
IndustryBiotechnology
Last report
Nov 5, 2026
Fiscal period
Q3 2026
-A$0.29 / -A$0.29
+2.34%beat
Revenue / Est. (AUD)
37.52M / 32.34M
+16.03%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in AUD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
17.62M
19.25M
21.70M
26.11M
Cost of goods sold
3.30M
3.52M
3.94M
4.17M
Cost of revenue
3.30M
3.52M
3.94M
4.17M
Research and development expenses
5.69M
5.63M
5.08M
4.70M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
19.03M
18.90M
19.54M
19.87M
Operating expense
24.72M
24.53M
24.62M
24.57M
Total operating expenses
28.02M
28.05M
28.56M
28.74M
Operating income
-10.41M
-8.80M
-6.86M
-2.63M
Other non operating income
737.00K
-95.00K
-12.00K
-2.05M
EBT including unusual items
-11.64M
-10.62M
-7.63M
-6.16M
EBT excluding unusual items
-11.04M
-10.32M
-7.83M
-6.16M
Income tax expense
-17.00K
-11.00K
33.00K
65.00K
Effective tax rate
0.15%
0.10%
-0.43%
-1.06%
Other operating expenses
-
-
-
-
Net income
-11.62M
-10.61M
-7.66M
-6.22M
Net profit margin
-65.97%
-55.12%
-35.31%
-23.83%
Earnings per share
-
-
-
-
Interest and investment income
200.00K
-
500.00K
-
Interest expense
-1.55M
-1.42M
-1.46M
-1.48M
Net interest expenses
-1.35M
-1.42M
-963.00K
-1.48M
Depreciation and amortization charges
-
-
-
-
EBITDA
-9.76M
-8.18M
-6.25M
-2.04M
Gain or loss from assets sale
5.00K
55.00K
188.00K
93.00K
Upcoming events
AI content may include mistakes. Learn more
Google apps